FDA issues a surprise refusal to review Moderna's mRNA-based flu vaccine filing, despite earlier agreement on trial design.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results